Objectives: Sarcopenia is the progressive loss of muscle mass and strength, and has a risk of adverse outcomes such as disability, poor quality of life and death. As prognosis depends not only on disease aggressiveness, but also on a patient's physical condition, sarcopenia can predict survival in patients with various cancer types. However, its effects on postoperative prognosis in patients with localized non-small cell lung cancers (NSCLC) have never been reported. Methods: We retrospectively investigated 215 male patients with pathological Stage I NSCLC. L3 muscle index is defined as the cross-section area of muscle at the third lumbar vertebra level, normalized for height, and is a clinical measurement of sarcopenia. We then investigated the effect of preoperative sarcopenia on their postoperative prognosis. Results: Our 215 subjects included 30 patients with sarcopenia. Sarcopenia was significantly associated with body mass index, nutritional condition, serum CYFRA 21-1 level and pathological stage, but not with preoperative respiratory function or performance status. Frequency of postoperative complications, length of postoperative hospital stay, thoracic drainage period or causes of death were not correlated with the presence of sarcopenia. The sarcopenia group had a significantly shorter median overall survival (32 months) than the no-sarcopenia group. Conclusion: Sarcopenia might not affect short-term outcomes in patients with early-stage lung cancer. Sarcopenia was a predictor of poor prognosis in male patients with Stage I NSCLC. As sarcopenic patients with NSCLC patients are at risk for significantly worse outcomes, their treatments require careful planning, even for those with Stage I disease.
Introduction
Sarcopenia is the progressive loss of muscle mass and strength, and has a risk of adverse outcomes such as disability, poor quality of life and death (1) . Depletion of skeletal muscle mass is the result of imbalance between pathways that favor protein synthesis and those favoring breakdown (2) . More than 50% of patients with advanced cancer suffer from sarcopenia (3) . As prognosis depends not only on disease aggressiveness, but also on a patient's physical condition, loss of skeletal muscle mass can predict survival in patients with various cancer types (4) (5) (6) .
Although several studies have addressed the relationship between sarcopenia and prognosis in patients with advanced disease, its effects on postoperative prognosis in patients with localized non-small cell lung cancers (NSCLC) has never been reported. Nakagawa et al., whose study included patients with NSCLC at various stages, reported that patients with low body mass index (BMI) had poor prognosis after surgery (7) . We hypothesized that sarcopenia was a predictor of postoperative prognosis in patients with localized NSCLC.
Patients and methods
Of 725 patients who underwent lobectomies or segmentectomies with mediastinal lymph node dissection for primary lung cancer at our hospital from January 2003 to December 2012, we retrospectively investigated 215 male patients with pathological Stage I NSCLC. Patients who had preoperative treatments, histories of malignancies in other organs, or whose disease was not completely removed were excluded. Informed consent about applications of their examination outcomes and datum of clinical courses to clinical studies had been obtained before surgery in all patients. The local institutional ethics committee approved this study.
Cross-sectional area (cm 2 ) of skeletal muscle at the third lumbar vertebra (L3) level on computed tomography scans (CTs) is a recognized measure of systemic muscle mass (8) . L3 muscle index (L3MI) is defined as the cross-section area of muscle at the third lumbar vertebra level, normalized for height (cm 2 /m 2 ; as with BMI), and is a clinical measurement of sarcopenia (9); i.e. L3MI = cross-sectional area (cm 2 ) of skeletal muscle at the L3/height (m) 2 Yoshizumi et al. (10) found the measured skeletal muscle area at the third lumbar vertebra was significantly correlated with body surface area (BSA); and create a formula to calculate skeletal muscle using BSA: BSA (m We used the formula to calculate L3MI for our male patients with pathological Stage I NSCLC, and used 49 cm 2 /m 2 as the cutoff value for sarcopenia. We then investigated the effect of preoperative sarcopenia on their postoperative prognosis and other clinical factors. Blood samples were harvested within 1 month before the surgery. Body height and weight were measured at the time of hospital admission. A cutoff value of age (68 years old) was calculated according to median age of patients in this study. A cutoff value of BMI (18.5 kg/m 2 ) was calculated according to a guideline from World Health Organization (11) . Cutoff values of tumor markers were calculated according to institutional cutoff values and previous reports (12) (13) (14) . Prolonged air leakage was defined as air leakage that required pleurodesis or additional thoracic drainage tube placement. Differences in clinicopathological factors between those with and without sarcopenia were assessed using the Mann-Whitney U-test and the χ 2 test. Overall survival (OS) and disease-free survival (DFS) were analyzed using the Kaplan-Meier method; differences were assessed using the log-rank test. Independent risk factors associated with survival were calculated using Cox proportional hazard model. P < 0.05 in two-tailed test was considered significant. Statistical analysis was performed using JMP 10 software (SAS Institute, Cary, NC, USA).
Results
Our 215 subjects included 30 patients with sarcopenia and 185 patients without sarcopenia. Figure 1 shows actual values for L3MI in sarcopenic and non-sarcopenic groups. Characteristics of patients according to the presence of sarcopenia are shown in Table 1 . Sarcopenia was significantly associated with BMI, nutritional condition, serum CYFRA 21-1 level and pathological stage, but not with preoperative respiratory function or performance status (PS). Their median follow-up period was 61 months, during which 49 patients had recurrent disease and 90 patients died. The sarcopenia group had a significantly shorter median OS (32 months) than the no-sarcopenia group (112 months, P < 0.01; Fig. 2 ). Patients with sarcopenia also had shorter DFS, although not significantly so (P = 0.097, Fig. 3 ). In patients with pathological Stage IA disease, sarcopenic group had a poor prognostic tendency (P = 0.058, Fig. 4 ). In patients with pathological Stage IB disease, sarcopenic group had a significantly poor prognosis (P < 0.01, Fig. 5 ).
In univariate analysis, age ≥68 years, BMI < 18.5 kg/m 2 , sarcopenia, serum CYFRA 21-1 > 3.5 ng/ml and pathological stage were significant predictors of poor prognosis. When these factors and performance status were subjected to multivariate analysis age and sarcopenia were independent predictors ( Table 2) . Although the two groups did not significantly differ in frequency of postoperative complications, length of postoperative hospital stay, thoracic drainage period or causes of death, execution status of adjuvant chemotherapy was significantly worse in the sarcopenia group (Table 3) .
Discussion
In this study, preoperative sarcopenia was an independent predictor of poor prognosis in male patients with pathological Stage I NSCLC. Especially, sarcopenia is a significantly poor prognostic factor in patients with pathological Stage IB disease. In patients with pathological Stage IA disease, sarcopenic group had poor prognostic tendency, although not significantly. This reason might be small number of sarcopenic patients in pathological Stage IA group. Patients with sarcopenia tended to have shorter DFS compared with those without sarcopenia, but did not significantly differ in frequency of postoperative complications or length of hospital stay. Sarcopenia might not affect short-term outcomes in patients with early-stage lung cancer. Host-related factors and/or tumor-related factors might derive wasting of skeletal muscle tissue (2) . Because tumor size was significantly correlated with presence or absence of sarcopenia, tumor-related factors might be a primary trigger for sarcopenia in this study population. Additionally, since sarcopenic condition other than degree of pathological stage was one of the independent prognostic factors under multivariate analysis, the malignant potentials leading sarcopenic condition might have greater influence on prognosis than tumor size in itself.
Early in this study period, benefit of adjuvant chemotherapy for Stage IB patients had been reported (15) . Benefit of adjuvant chemotherapy for Stage IA (>2 cm) patients were reported late in this study period (16) . Therefore, the execution status of adjuvant chemotherapy for Stage IA patients was extremely low in this study. Because a criterion in avoidance of adjuvant chemotherapy was not established, the judgment was depended on each physician's empirical concept. No significant difference in conventional physical examination findings (such as respiratory function test and PS) was observed between sarcopenic and non-sarcopenic groups. As sarcopenia may be difficult to diagnose through a conventional examination, general conditions were classified as being in the normal range for most sarcopenic patients. However, adjuvant chemotherapy was avoided for patients with sarcopenic condition at each physician's judgment. Sarcopenia is reportedly associated with increased risk of toxicity in patients with colon cancer who undergo adjuvant chemotherapy (17) . If patients who will get benefit from adjuvant chemotherapy can be selected, a prognosis of patients with sarcopenia may improve. Further investigation of the effects of chemotherapy on patients with sarcopenia is warranted.
Tumor-related wasting of skeletal muscle tissue is considered to be induced by a tumor-associated systemic inflammation. Systemic inflammatory signals including interleukin (IL)-1, IL-6, and tumor necrosis factor-α, activated muscular nuclear factor-kappa B signaling and subsequent ubiquitin proteasome system (UPS)-mediated proteolysis (2) . Cancer cachexia is often evident in the progressive stage. Pre-cachexia is considered an initial face of cachexia (18) , in which metabolic changes, such as systemic inflammation, result in minor body weight loss, but do not yet significantly deplete skeletal muscle mass or impair physical function (19) . The study of Op den Kamp et al. included many pre-cachectic patients with Stage I NSCLC, and showed pre-cachexia often progressed to cachexia. UPS-mediated proteolysis is not increased in pre-cachexia (19) . Sarcopenia group might have included patients who were changing from pre-cachexic to cachexic, of which the sarcopenia could have been an initial symptom. These patients were more likely to suffer from poor response to therapies and worse prognosis.
In patients with chronic obstructive pulmonary disease, pulmonary rehabilitation led to a reversal of sarcopenia. Duration of their rehabilitation program was 8 weeks (20) . Whole-body vibration training was reported to have positive effects on muscle performance in people with sarcopenia. Their training period was 12 weeks (21) . Because a period between diagnosis and surgery is short, a preoperative rehabilitation intended to recovery from sarcopenia may be impossible in patients with lung cancer. An anti-inflammatory treatment, such as a monoclonal antibody to IL-6, seemed to be of benefit in ameliorating cancer related cachexia and anemia in preclinical and phase I and II studies of patients with NSCLC (22) . Antiinflammatory treatments may be benefit for sarcopenic condition, when wasting of skeletal muscle tissue was induced by tumorrelated inflammatory cytokines-mediated proteolysis. Confirmation of perioperative selective anti-inflammatory therapy was desired.
Low BMI before surgery reported has a negative effect on surgical outcomes for patients with NSCLC (7). In our univariate analysis, sarcopenia and BMI were significant predictors of poor prognosis in patients with Stage I NSCLC, although only sarcopenia survived multivariate analysis. Systemic muscle mass may reflect the ability to survive lung cancer, and could be a new prognostic factor for the treatment of NSCLC.
This study had some limitations. Furthermore, the formula used in this study was calculated using physical findings of healthy adults. We used the formula because almost all patients in this study were classified as PS 0 and 1, and averages of BMI in this study were similar to those in Yoshizumi's report (10) . The skeletal muscle area could be calculated easily using the formula, and L3MI was established as an independent predictor of poor prognosis. Using the formula could delete the measurement error of L3MI, and patients can avoid unnecessary CT at lumbar vertebra level. However, average age in this study was mismatched to that in Yoshizumi's report (68.1 and 43.4, respectively). In Yoshizumi's report it was reported that skeletal muscle area was not significantly related to age (10) . Using the formula for patients with pathological Stage I NSCLC in this study might be acceptable. Sarcopenia was an independent predictor of poor prognosis in patients with Stage I NSCLC. Sarcopenia can be difficult to assess by conventional physical examinations, but L3MI is a reliable quantitative indicator. As sarcopenic patients with NSCLC patients are at risk for significantly worse outcomes, their treatments require careful planning. Values are median (range).
